Stockscreener 앱 받기
1.48
1.37%
0.02
시간 외 거래:
1.45
-0.03
-2.03%
전일 마감가:
$1.46
열려 있는:
$1.47
하루 거래량:
119.47K
Relative Volume:
1.26
시가총액:
$12.36M
수익:
$10.16M
순이익/손실:
$-47.57M
주가수익비율:
-0.1796
EPS:
-8.24
순현금흐름:
$-42.73M
1주 성능:
-38.08%
1개월 성능:
-50.67%
6개월 성능:
-71.21%
1년 성능:
-87.99%
1일 변동 폭
$1.47
$1.61
1주일 범위
$1.4001
$2.6172
52주 변동 폭
$1.4001
$17.49
Curis Inc Stock (CRIS) Company Profile
명칭
Curis Inc
전화
617-503-6500
주소
128 SPRING STREET, LEXINGTON, MA
CRIS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRIS
Curis Inc
|
1.48 | 12.36M | 10.16M | -47.57M | -42.73M | -8.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Curis Inc Stock (CRIS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-17 | 개시 | Truist | Buy |
| 2022-04-04 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-10-13 | 개시 | Raymond James | Outperform |
| 2021-03-25 | 개시 | B. Riley Securities | Buy |
| 2020-07-29 | 개시 | Laidlaw | Buy |
| 2020-07-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2016-03-02 | 개시 | Sun Trust Rbsn Humphrey | Buy |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-08-11 | 개시 | FBR Capital | Outperform |
| 2015-01-22 | 재확인 | Oppenheimer | Outperform |
| 2015-01-21 | 재확인 | ROTH Capital | Buy |
| 2014-05-09 | 재확인 | Oppenheimer | Outperform |
| 2013-10-02 | 개시 | Robert W. Baird | Outperform |
| 2013-09-30 | 개시 | Chardan Capital Markets | Buy |
| 2012-11-14 | 개시 | Stifel Nicolaus | Hold |
| 2012-01-31 | 재확인 | Brean Murray | Buy |
| 2012-01-31 | 재확인 | Summer Street Research | Buy |
| 2011-12-09 | 개시 | Oppenheimer | Outperform |
| 2011-10-06 | 개시 | Summer Street Research | Buy |
| 2011-09-22 | 개시 | MLV Capital | Buy |
| 2011-03-21 | 재확인 | Brean Murray | Buy |
| 2010-02-26 | 재확인 | Roth Capital | Buy |
| 2010-01-07 | 개시 | Roth Capital | Buy |
모두보기
Curis Inc 주식(CRIS)의 최신 뉴스
Curis to Present at Upcoming Healthcare Conference in April - The Victoria Advocate
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS) - simplywall.st
Curis stock plunges to 52-week low at $1.97 amid market challenges - Investing.com
Curis stock price target cut to $16 by H.C. Wainwright - Investing.com India
Curis, Inc. (NASDAQ:CRIS) Just Reported Full-Year Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Curis, Inc. (NASDAQ:CRIS) Q4 2024 Earnings Call Transcript - Insider Monkey
Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30% - simplywall.st
Curis: Q4 Earnings Snapshot - CT Insider
Curis Inc (CRIS) Q4 2024 Earnings Call Highlights: Financial Improvements and Promising ... - Yahoo Finance
Curis stock plunges to 52-week low at $1.97 amid market challenges By Investing.com - Investing.com South Africa
Curis (NASDAQ:CRIS) Price Target Lowered to $16.00 at HC Wainwright - Defense World
Curis Inc. Reports Q4 2024 Progress and Financials - TipRanks
Curis Inc. Earnings Call: Progress Amidst Challenges - TipRanks
Curis targets accelerated approval for emavusertib in PCNSL with 12-18 month enrollment timeline - MSN
Earnings call transcript: Curis Q4 2024 reveals reduced losses - Investing.com India
Curis Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Curis eyes accelerated approval for cancer drug emavusertib - Investing.com India
Curis Provides Fourth Quarter 2024 Business Update - PR Newswire
Curis Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Curis (NASDAQ:CRIS) Coverage Initiated at StockNews.com - Defense World
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 - Quantisnow
Biotech Alert: Curis Sets Date for Q4 EarningsKey Updates on IRAK4 Inhibitor Program Expected - Stock Titan
Curis Inc Entered A Purchase Agreement To Sell 2 Million Shares Of Common Stock - Marketscreener.com
Curis stock hits 52-week low at $2.54 amid sharp annual decline - Investing.com Australia
Curis stock hits 52-week low at $2.54 amid sharp annual decline By Investing.com - Investing.com South Africa
StockNews.com Initiates Coverage on Curis (NASDAQ:CRIS) - Defense World
Health Care Providers To Pay Back Almost $2 Million In Medicare Fraud - Newsweek
Curis stock touches 52-week low at $2.83 amid sharp yearly decline - Investing.com Australia
Curis Inc faces potential Nasdaq delisting By Investing.com - Investing.com Australia
Curis, Inc. to Host Earnings Call - ACCESS Newswire
Curis Inc faces potential Nasdaq delisting - Investing.com
Investor Network: Curis, Inc. to Host Earnings Call - ACCESS Newswire
Curis (CRIS) Expected to Announce Quarterly Earnings on Thursday - Defense World
CURIS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
BostInnoHappy New Year! | Inno Approved Events - The Business Journals
Diddy, Jay-Z Rape Lawsuit Dropped Amid Legal Ethics Battle - Law360
CRISCuris Provides Second Quarter 2024 Financial and Operating Update - br.ADVFN.com
Curis (CRIS) Projected to Post Earnings on Thursday - Defense World
Jay-Z Sex Assault Suit Invalid Under Law, Rapper Says - Law360
Jay-Z Blasts Buzbee For 'Reputation-Destroying Allegations' - Law360
Cantor Fitzgerald Comments on Curis FY2025 Earnings - Defense World
Earnings call transcript: Curis Q4 2024 reveals reduced losses By Investing.com - Investing.com Australia
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Curis stock plunges to 52-week low, now at $3.0 By Investing.com - Investing.com Nigeria
Curis stock plunges to 52-week low, now at $3.0 - Investing.com
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
Critical Comparison: Curis (NASDAQ:CRIS) vs. Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Curis, Inc. (NASDAQ:CRIS) Short Interest Down 39.4% in December - Defense World
Curis Inc (CRIS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.00%
자본화:
|
볼륨(24시간):